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Abstract: AbstractsThis study aims to investigate the two-year clinical outcomes between first-
generation (1G) and second-generation (2G) drug-eluting stents (DES) based on pre-percutaneous
coronary intervention (PCI) thrombolysis in myocardial infarction (TIMI) flow grade (pre-TIMI) in
patients with ST-segment elevation myocardial infarction (STEMI). Overall, 17,891 STEMI patients
were classified into two groups: pre-TIMI 0/1 group (n = 12,862; 1G-DES (n = 4318), 2G-DES (n = 8544))
and pre-TIMI 2/3 group (n = 5029; 1G-DES (n = 2046), 2G-DES (n = 2983)). During a two-year follow-
up period, major adverse cardiac events (MACEs) defined as all-cause death, recurrent myocardial
infarction (re-MI), or any repeat revascularization and stent thrombosis (ST) were considered as the
primary and the secondary outcomes. In the pre-TIMI 0/1 and 2/3 groups, the cumulative incidences
of MACEs (adjusted hazard ratio (aHR): 1.348, p < 0.001, and aHR: 1.415, p = 0.02, respectively) and
any repeat revascularization (aHR: 1.938, p < 0.001, and aHR: 1.674, p = 0.001, respectively) were
significantly higher in the 1G-DES than in the 2G-DES. However, sirolimus-eluting stent showed
similar cumulative incidence of any repeat revascularization compared with zotarolimus-eluting
stent and biolimus-eluting stent in both pre-TIMI 0/1 and 2/3 groups. The cumulative incidences
of all-cause death, re-MI, and ST were similar between the 1G-DES and 2G-DES groups. In this
study, 2G-DES showed better clinical outcomes than 1G-DES concerning MACEs and any repeat
revascularization regardless of pre-TIMI. However, more research is needed to support these results.
Keywords: ST-segment elevation myocardial infarction; percutaneous coronary intervention;
reperfusion; stents
1. Introduction
Although second-generation drug-eluting stents (2G-DES) have a newly advanced
biocompatible polymer compared to first-generation (1G-DES), their comparative results
are conflicting [1–3]. Previous studies [4,5] demonstrated that pre-percutaneous coronary
intervention (pre-PCI) thrombolysis in myocardial infarction (TIMI) flow grade (pre-TIMI)
was a significant predictor of survival in ST-segment elevation myocardial infarction
J. Clin. Med. 2021, 10, 367. https://doi.org/10.3390/jcm10020367 https://www.mdpi.com/journal/jcm
J. Clin. Med. 2021, 10, 367 2 of 14
(STEMI) patients. If the blood supply goes down, remnant oxygen in the ischemic area
of the myocardium is disappeared within seconds. Therefore, after a certain duration of
complete ischemia, there is no treatment strategy that can salvage ischemic myocardium [6].
However, cardiomyocytes that are exposed to low residual oxygen levels may be able to
maintain sufficient adenosine triphosphate to survive for an extended period, even if the
adenosine triphosphate is insufficient to enable their contraction [6]. Hence, pre-TIMI 0/1
and pre-TIMI 2/3 [7] are apparently different milieu in patients with STEMI. Recently,
Yildiz et al. [8] suggested that the pre-TIMI was closely linked with percentage of patients
getting PCI, the use of glycoprotein IIb/IIIa, and stent type. Therefore, pre-TIMI can be
another significant variable for comparing major clinical outcomes between 1G-DES and
2G-DES. However, the majority of previous such comparative studies between these two
different generation DES were not based on pre-TIMI in patients with STEMI [9,10]. Here,
we compared the two-year major clinical outcomes between 1G-DES and 2G-DES based on
these two different pre-TIMIs of the culprit coronary artery in patients with STEMI.
2. Materials
2.1. Study Design and Population
From the Korea acute myocardial infarction (AMI) registry (KAMIR) [11], 24,549
STEMI patients who received successful stent implantation between November 2005 and
June 2015 were evaluated. The characteristics of the KAMIR are already published [11].
Among them, those with incomplete laboratory results (n = 4004 (16.3%)), who were lost
to follow-up (n = 994 (4.0%)), who received bare-metal stent (n = 1439 (5.9%)), or who
received 1G-DES and 2G-DES concomitantly (n = 221 (0.9%)) were excluded. Overall,
17,891 STEMI patients were classified into two groups: pre-TIMI 0/1 group (n = 12,862
(71.9%)) and pre-TIMI 2/3 group (n = 5029 (28.1%)). Thereafter, these two groups were
subdivided into patients who received 1G-DES (Group A1 (n = 4318 (33.6%)) and Group
A2 (n = 2046 (40.7%))) and those who received 2G-DES (Group B1 (n = 8544 (67.4%)) and
Group B2 (n = 2983 (59.3%))) (Figure 1). All patients provided written informed consent
before enrollment. During the follow-up period, any adverse events of the enrolled patients
were carefully monitored at the outpatient clinic, by phone calls, or by reviewing their
charts. Altogether, 17,891 STEMI patients completed the scheduled follow-up. Additionally,
an independent event-adjudicating committee evaluated all clinical events. The event
adjudication process was mentioned in a previous publication [11]. This study protocol
was approved by the ethics committee at each participating center and the Chonnam
National University Hospital Institutional Review Board (IRB) ethics committee (CNUH-
2011-172) according to the ethical guidelines of the 1975 Declaration of Helsinki.
2.2. Percutaneous Coronary Intervention (PCI) Procedure and Medical Treatment
We performed diagnostic coronary angiography (CAG) and PCI according to the stan-
dard techniques [12]. We loaded the loading doses of antiplatelet agents as follows: aspirin
200–300 mg, clopidogrel 300–600 mg, and ticagrelor 180 mg or prasugrel 60 mg. Dual an-
tiplatelet therapy (DAPT; combination of aspirin 100 mg/day and clopidogrel 75 mg/day
or ticagrelor 90 mg twice daily or prasugrel 5–10 mg/day) was recommended for at least
12 months. The individual operators were free to choose DAPT or triple antiplatelet therapy
(aspirin + clopidogrel + cilostazol (100 mg twice daily)) during the operation.
2.3. Study Definitions and Clinical Outcomes
We defined STEMI according to the current guidelines [13,14]. The degree of pre-TIMI
was assessed by the investigators [15]. During a two-year follow-up period, major adverse
cardiac events (MACEs) defined as all-cause death, recurrent myocardial infarction (re-MI),
or any repeat revascularization and stent thrombosis (ST) were considered as the primary
and the secondary outcomes. All-cause death consisted of cardiac death (CD) or non-CD.
Target lesion revascularization (TLR), target vessel revascularization (TVR), and non-TVR
were included in any repeat revascularization. The definitions of successful PCI, complete
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revascularization, incomplete revascularization, re-MI, TLR, TVR, and non-TVR were as
previously reported [16,17].
Figure 1. Flowchart. AMI, acute myocardial infarction; STEMI, ST-segment elevation myocardial
infarction; BMS, bare-metal stent; 1G-DES, first-generation drug-eluting stent; 2G-DES, second-
generation DES; Pre-PCI, pre-percutaneous coronary intervention; TIMI, thrombolysis in myocar-
dial infarction.
2.4. Statistical Analysis
Regarding continuous variables, we compared differences between groups using
the unpaired t-test. Data are expressed as mean ± standard deviation (SD) or as median
(quartiles 1–3). Regarding discrete variables, we compared intergroup differences using
the chi-square test or Fisher’s exact test. Data are expressed as counts and percentages.
Various clinical outcomes were estimated using Kaplan–Meier curve analysis, and inter-
group differences were compared using the log-rank test. Two-tailed p-values < 0.05 were
considered statistically significant. We tested all variables with p < 0.1 in the univariate
analysis. After univariate analysis, we tested all variables with p < 0.05 in the multivariate
analysis. These variables included the following: male, age, left ventricular ejection fraction
(LVEF), Killip class III/IV, systolic blood pressure, cardiogenic shock, cardiopulmonary
resuscitation (CRP) on admission, hypertension, diabetes mellitus (DM), dyslipidemia,
prior PCI, current smoker, peak creatine kinase myocardial band (CK-MB), peak troponin-I,
N-terminal pro-brain natriuretic peptide (NT-ProBNP), serum creatinine, total choles-
terol, triglyceride, high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol,
clopidogrel, ticagrelor, prasugrel, cilostazole, beta-blocker (BB), calcium channel blocker,
single-vessel disease, more than three diseased vessels, left anterior descending coronary
artery (infarct-related artery (IRA) and treated vessel), right coronary artery (IRA), Ameri-
can College of Cardiology/American Heart Association (ACC/AHA) type B1/B2/C lesion,
in-hospital glycoprotein IIb/IIIa inhibitor, intravascular ultrasound (IVUS), culprit-only
PCI, stent diameter, stent length, and number of deployed stents. Additionally, we evalu-
ated the cumulative incidence of any repeat revascularization according to deployed stent
type (Supplementary Tables S1–S3) using analysis of variance (ANOVA) or the Jonckheere-
Terpstra test. Because there are some issues of multiple comparisons and concern for
false-positive association during the analysis, we adjusted significance thresholds for each
comparison by using the Benjamini-Hochberg false discovery control procedure with
a set false discovery rate of 5% during a post-hoc analysis. Regarding categorical vari-
ables, we compared intergroup differences using the chi-square test or Fisher’s exact test.
All statistical analyses were performed using SPSS software version 20 (IBM, Armonk,
NY, USA).
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3. Results
3.1. Baseline Characteristics
Table 1 shows the baseline characteristics of the study population. In the pre-TIMI 0/1
(Groups A1 and B1) and 2/3 (Groups A2 and B2) groups, the mean LVEF was preserved
(≥50%). Significantly more patients in the pre-TIMI 0/1 group than in the pre-TIMI 2/3
group received in-hospital glycoprotein IIb/IIIa. The prescription rates of clopidogrel,
cilostazole, and calcium channel blockers as the discharge medications, more than three dis-
eased vessels, ACC/AHA type B1 lesion, multivessel PCI, number of deployed stents, and
mean serum creatinine and high-density lipoprotein-cholesterol levels were significantly
higher in the 1G-DES (Groups A1 and A2) groups than in the 2G-DES (Groups B1 and B2)
groups. In contrast, the number of men, number of patients requiring CPR on admission,
with dyslipidemia or previous PCI, prescription rates of ticagrelor, prasugrel, and BBs as
the discharge medications, patients with single-vessel disease, ACC/AHA type B2 lesions,
and culprit-only PCI, number of patients requiring IVUS, mean triglyceride level, and
mean deployed stent diameter were significantly higher in the 2G-DES groups than in
the 1G-DES groups. However, the mean door-to-balloon time and number of complete
revascularizations in case of multivessel PCI, and number of patients with cardiogenic
shock, hypertension, and diabetes mellitus, and the number who were current smokers,
were similar between the two groups.
Table 1. Baseline characteristics.
Variables
Pre-PCI TIMI 0/1 (n = 12,862) Pre-PCI TIMI 2/3 (n = 5029)
Group A1
1G-DES (n = 4318)
Group B1
2G-DES (n = 8554) p-Value
Group A2
1G-DES (n = 2046)
Group B2
2G-DES (n = 2983) p-Value
Male, n (%) 3199 (74.1) 6534 (76.5) 0.003 1533 (74.9) 2270 (76.1) 0.342
Age, years 62.4 ± 12.6 62.3 ± 12.7 0.687 62.6 ± 12.4 63.3 ± 12.8 0.062
LVEF, % 50.2 ± 11.3 50.5 ± 10.8 0.161 51.9 ± 11.8 51.7 ± 11.3 0.539
BMI, kg/m2 24.0 ± 3.1 24.2 ± 3.2 0.051 23.8 ± 3.1 23.9 ± 3.2 0.198
Killip classification
I 3165 (73.3) 6554 (76.7) <0.001 1570 (76.7) 2431 (81.5) <0.001
II 624 (14.5) 969 (11.3) <0.001 259 (12.7) 246 (8.2) <0.001
III 225 (5.2) 441 (5.2) 0.901 118 (5.8) 161 (5.4) 0.573
IV 305 (7.1) 580 (6.8) 0.561 99 (4.8) 145 (4.9) 0.971
SBP, mmHg 125.2 ± 28.2 126.9 ± 28.6 0.001 128.2 ± 27.2 128.4 ± 27.7 0.785
DBP, mmHg 77.5 ± 17.1 78.0 ± 17.6 0.141 78.7 ± 16.2 78.5 ± 16.2 0.643
Cardiogenic shock, n (%) 305 (7.1) 580 (6.8) 0.561 99 (4.8) 145 (4.9) 0.971
CPR on admission, n (%) 85 (2.0) 525 (6.1) <0.001 57 (2.8) 159 (5.3) <0.001
Hypertension, n (%) 1940 (44.9) 3849 (45.0) 0.896 934 (45.7) 1398 (46.9) 0.396
Diabetes mellitus, n (%) 1068 (24.7) 2047 (24.0) 0.332 532 (26.0) 792 (26.6) 0.664
Dyslipidemia, n (%) 359 (8.3) 922 (10.8) <0.001 170 (8.3) 322 (10.8) 0.004
Previous MI, n (%) 109 (2.5) 259 (3.0) 0.103 42 (2.1) 88 (3.0) 0.057
Previous PCI, n (%) 143 (3.3) 387 (4.5) 0.001 66 (3.2) 142 (4.8) 0.008
Previous CABG, n (%) 15 (0.3) 27 (0.3) 0.768 5 (0.2) 6 (0.2) 0.766
Previous CVA, n (%) 237 (5.5) 415 (4.9) 0.123 102 (5.0) 176 (5.9) 0.163
Previous HF, n (%) 40 (0.9) 70 (0.8) 0.533 16 (0.8) 25 (0.8) 0.874
Current smokers, n (%) 2064 (47.8) 4004 (46.9) 0.315 987 (48.2) 1364 (45.7) 0.079
Peak CK-MB, mg/dL 209.9 ± 282.3 191.0 ± 244.1 <0.001 138.8 ± 244.9 139.6 ± 225.6 0.915
Peak Troponin-I, ng/mL 64.2 ± 111.1 77.1 ± 294.1 0.001 46.6 ± 68.6 48.2 ± 98.7 0.508
Blood glucose, mg/dL 176.3 ± 80.0 177.4 ± 78.4 0.470 171.5 ± 79.0 173.1 ± 79.0 0.472
NT-ProBNP (pg/mL) 1841.9 ± 3595.0 1638.1 ± 4993.8 0.008 1879.2 ± 3584.3 1884.9 ± 4338.3 0.959
High-sensitivity CRP (mg/dL) 13.4 ± 57.8 9.1 ± 37.4 <0.001 10.5 ± 79.3 7.2 ± 26.9 0.068
Serum creatinine (mg/L) 1.12 ± 1.13 1.08 ± 1.17 0.035 1.16 ± 1.66 1.06 ± 0.90 0.011
Total cholesterol, mg/dL 184.9 ± 44.6 184.7 ± 45.0 0.877 184.4 ± 42.8 181.1 ± 44.1 0.010
Triglyceride, mg/L 127.3 ± 110.5 137.4 ± 112.0 <0.001 125.0 ± 102.9 133.6 ± 109.9 0.006
HDL cholesterol, mg/L 45.0 ± 20.0 43.5 ± 15.8 <0.001 46.1 ± 29.8 43.2 ± 15.2 <0.001
LDL cholesterol, mg/L 118.1 ± 38.4 116.6 ± 39.1 0.059 119.1 ± 44.2 113.5 ± 42.5 <0.001
Discharge medications, n (%)
Aspirin, n (%) 4192 (97.1) 8237 (96.3) 0.537 1987 (97.1) 2833 (95.0) 0.152
Clopidogrel, n (%) 4202 (97.3) 7154 (83.7) <0.001 1998 (97.7) 2514 (84.3) <0.001
Ticagrelor, n (%) 6 (0.1) 687 (8.0) <0.001 5 (0.2) 227 (7.6) <0.001
Prasugrel, n (%) 6 (0.1) 409 (4.8) <0.001 2 (0.1) 149 (5.0) <0.001
Cilostazole, n (%) 1456 (33.7) 1493 (17.5) <0.001 739 (36.1) 508 (17.0) <0.001
Beta-blockers, n (%) 3004 (69.6) 6829 (79.4) <0.001 1508 (73.7) 2429 (81.4) <0.001
ACEIs/ARBs, n (%) 3281 (76.0) 6528 (76.4) 0.597 1632 (79.8) 2353 (78.9) 0.447
CCBs, n (%) 266 (6.2) 250 (2.9) <0.001 162 (7.9) 149 (5.0) <0.001
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Table 1. Cont.
Variables
Pre-PCI TIMI 0/1 (n = 12,862) Pre-PCI TIMI 2/3 (n = 5029)
Group A1
1G-DES (n = 4318)
Group B1
2G-DES (n = 8554) p-Value
Group A2
1G-DES (n = 2046)
Group B2
2G-DES (n = 2983) p-Value
Lipid-lowering agents 3887 (90.0) 7613 (89.0) 0.879 1811 (88.5) 2639 (88.5) 0.977
IRA
Left main, n (%) 41 (0.9) 82 (1.0) 0.996 46 (2.2) 81 (2.7) 0.315
LAD, n (%) 2144 (49.7) 4271 (50.0) 0.719 1275 (62.3) 1726 (57.9) 0.002
LCx, n (%) 450 (10.4) 773 (9.0) 0.012 174 (8.5) 252 (8.4) 0.944
RCA, n (%) 1683 (39.0) 3418 (40.0) 0.260 551 (26.9) 924 (31.0) 0.002
Treated vessel
Left main, n (%) 60 (1.4) 120 (1.4) 0.997 71 (3.5) 113 (3.8) 0.593
LAD, n (%) 2399 (55.6) 4836 (56.6) 0.260 1399 (68.4) 1951 (65.4) 0.028
LCx, n (%) 698 (16.2) 1283 (15.0) 0.092 349 (17.1) 527 (17.7) 0.576
RCA, n (%) 1856 (43.0) 3757 (44.0) 0.285 681 (33.3) 1102 (36.9) 0.008
Extent of CAD
Single-vessel disease, n (%) 2055 (47.6) 4737 (55.4) <0.001 956 (46.7) 1523 (51.1) 0.003
Two-vessel disease, n (%) 1339 (31.0) 2437 (28.5) 0.003 643 (31.4) 891 (29.9) 0.238
≥Three-vessel disease, n (%) 924 (21.4) 1370 (16.0) <0.001 447 (21.8) 569 (19.1) 0.016
ACC/AHA lesion type
Type B1, n (%) 602 (13.9) 1075 (12.6) 0.031 444 (21.7) 521 (17.5) <0.001
Type B2, n (%) 921 (21.3) 2420 (28.3) <0.001 627 (30.6) 1188 (39.8) <0.001
Type C, n (%) 2353 (54.5) 4427 (51.8) 0.004 794 (38.8) 1051 (35.2) 0.010
In-hospital GP IIb/IIIa
inhibitor 618 (14.3) 1862 (21.8) <0.001 156 (7.6) 447 (15.0) <0.001
IVUS, n (%) 267 (6.2) 1397 (16.4) <0.001 144 (7.0) 623 (20.9) <0.001
OCT, n (%) 0 (0.0) 21 (0.2) 0.001 0 (0.0) 12 (0.4) 0.002
FFR, n (%) 4 (0.1) 65 (0.8) <0.001 2 (0.1) 34 (1.1) <0.001
Drug-eluting stents
SES, n (%) 2289 (47.0) 1141 (55.8)
PES, n (%) 2029 (53.0) 905 (44.2)
ZES, n (%) 3336 (39.0) 1116 (37.4)
EES, n (%) 3889 (45.5) 1331 (44.6)
BES, n (%) 1062 (12.4) 391 (13.1)
Others, n (%)a 257 (3.0) 145 (4.9)
Door-to-balloon time 59.5 (45.5–72.0) 60.0 (45.0–76.0) 0.688 60.0 (44.0–75.0) 60.5 (44.0–77.0) 0.574
Culprit-only PCI 1444 (33.4) 4569 (53.5) <0.001 636 (31.1) 1487 (49.8) <0.001
Multivessel PCI 2874 (66.6) 3975 (46.5) <0.001 1410 (68.9) 1496 (50.2) <0.001
Completeness of PCI
CR, n (%) 1954 (68.0) 2762 (69.5) 0.180 988 (70.1) 1069 (71.5) 0.414
IR, n (%) 920 (32.0) 1,213 (30.5) 0.180 422 (29.9) 427 (28.5) 0.414
Stent diameter (mm) 3.15 ± 0.38 3.19 ± 0.42 <0.001 3.15 ± 0.37 3.19 ± 0.42 0.002
Stent length (mm) 26.4 ± 6.7 26.6 ± 10.1 0.148 25.4 ± 6.8 25.5 ± 9.9 0.779
Number of stents 1.42 ± 0.74 1.36 ± 0.68 <0.001 1.50 ± 0.80 1.42 ± 0.73 <0.001
Values are means ± standard deviation (SD) or numbers and percentages or as median (quartiles 1–3). The p-values for continuous data
were obtained from the unpaired t-test. The p-values for categorical data from chi-square or Fisher’s exact test. 1G-DES, first-generation
drug-eluting stent; 2G-DES, second-generation DES; Pre-PCI, pre-percutaneous coronary intervention; TIMI, thrombolysis in myocardial
infarction; LVEF, left ventricular ejection fraction; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; STEMI,
ST-segment elevation myocardial infarction, NSTEMI, non-STEMI; CPR, cardiopulmonary resuscitation; MI, myocardial infarction; PCI,
percutaneous coronary intervention; CABG, coronary artery bypass graft; HF, heart failure; CVA, cerebrovascular accidents; CK-MB,
creatine kinase myocardial band; NT-ProBNP, N-terminal pro-brain natriuretic peptide; Hs-CRP, high-sensitivity-C-reactive protein; HDL,
high-density lipoprotein; LDL, low-density lipoprotein; ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor
blockers; CCBs, calcium channel blockers; IRA, infarct-related artery; LAD, left anterior descending coronary artery; LCx, left circumflex
coronary artery; RCA, right coronary artery; CAD, coronary artery disease; ACC/AHA, American College of Cardiology/American Heart
Association; GP, glycoprotein; IVUS, intravascular ultrasound; OCT, optical coherence tomography; FFR, fractional flow reserve; SES,
sirolimus-eluting stent; PES, paclitaxel-eluting stent; ZES, zotarolimus-eluting stent; EES, everolimus-eluting stent; BES, biolimus-eluting
stent; CR, complete revascularization; IR, incomplete revascularization.
3.2. Clinical Outcomes
The cumulative incidence of major clinical outcomes during the two-year follow-up period
is shown in Tables 2 and 3, and Figures 2 and 3. Supplementary Table S4 shows the independent
predictors for MACEs and any repeat revascularization in the total study population at 2 years.
In the total study population, after adjustment, the cumulative incidence of MACEs (adjusted
hazard ratio (aHR): 1.210; 95% confidence interval (CI): 1.057–1.398; p = 0.005), all-cause death
(aHR: 1.350; 95% CI: 1.095–1.699; p = 0.006), and CD (aHR: 1.498; 95% CI: 1.180–1.910; p = 0.001)
were significantly higher in the pre-TIMI 0/1 group than in the pre-TIMI 2/3 group. The
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cumulative incidence of MACEs (aHR: 1.233; 95% CI: 1.095–1.388; p < 0.001) and any repeat
revascularization (aHR: 1.832; 95% CI: 1.528–2.197; p < 0.001) were significantly higher in the
1G-DES (Groups A1 and A2) than in the 2G-DES (Groups B1 and B2) groups.
Table 2. Clinical outcomes by Kaplan–Meier analysis and Cox-proportional hazard ratio analysis at 2 years.
Pre-PCI TIMI 0/1
Cumulative Events (%) Unadjusted Adjusted a









MACEs 517 (12.0) 826 (10.0) 0.001 1.201 (1.076–1.341) 0.001 1.348 (1.184–1.536) <0.001 0.124
All-cause death 246 (5.7) 503 (6.0) 0.534 1.050 (0.901–1.222) 0.535 1.014 (0.823–1.250) 0.893 0.535
Cardiac death 226 (5.2) 440 (5.2) 0.941 1.006 (0.857–1.181) 0.941 1.086 (0.867–1.361) 0.474 0.941
Re-MI 58 (1.4) 134 (1.7) 0.161 1.246 (0.915–1.696) 0.162 1.366 (0.968–1.926) 0.076 0.017
Any revascularization 234 (5.7) 240 (3.2) <0.001 1.832 (1.530–2.193) <0.001 1.938 (1.605–2.340) <0.001 0.682
ST (definite or probable) 44 (1.0) 65 (0.8) 0.131 1.341 (0.915–1.967) 0.133 1.145 (0.951–2.106) 0.102 0.133
Pre-PCI TIMI 2/3
Cumulative Events (%) Unadjusted Adjusted b









MACEs 209 (10.2) 257 (9.1) 0.144 1.146 (0.954–1.375) 0.144 1.415 (1.142–1.953) 0.002 0.144
All-cause death 87 (4.3) 137 (4.7) 0.463 1.106 (0.845–1.447) 0.464 1.311 (0.920–1.964) 0.133 0.464
Cardiac death 76 (3.7) 107 (3.7) 0.883 1.022 (0.762–1.372) 0.884 1.512 (1.010–2.532) 0.053 0.884
Re-MI 29 (1.5) 46 (1.7) 0.557 1.149 (0.722–1.830) 0.557 1.101 (0.665–1.924) 0.708 0.391
Any revascularization 109 (5.5) 94 (3.5) 0.001 1.605 (1.218–2.115) 0.001 1.674 (1.244–2.352) 0.001 0.275
ST (definite or probable) 13 (0.6) 24 (0.8) 0.490 1.267 (0.645–2.489) 0.492 1.178 (0.585–2.670) 0.646 0.492
1G-DES














MACEs 517 (12.0) 209 (10.2) 0.037 1.186 (1.010–1.393) 0.038 1.222 (1.026–1.454) 0.024 0.158
All-cause death 246 (5.7) 87 (4.3) 0.015 1.352 (1.059–1.726) 0.016 1.459 (1.101–1.932) 0.008 0.218
Cardiac death 226 (5.2) 76 (3.7) 0.008 1.421 (1.096–1.843) 0.008 1.536 (1.136–2.157) 0.005 0.175
Re-MI 58 (1.4) 29 (1.5) 0.851 1.043 (0.668–1.629) 0.852 1.244 (0.762–2.030) 0.383 0.506
Any revascularization 234 (5.7) 109 (5.5) 0.774 1.034 (0.824–1.298) 0.774 1.090 (0.858–1.386) 0.480 0.774
ST (definite or probable) 44 (1.0) 13 (0.6) 0.130 1.606 (0.865–2.981) 0.134 1.735 (0.914–3.301) 0.092 0.134
2G-DES














MACEs 826 (10.0) 257 (9.1) 0.069 1.138 (0.990–1.310) 0.069 1.242 (1.046–1.484) 0.013 0.089
All-cause death 503 (6.0) 137 (4.7) 0.007 1.296 (1.073–1.565) 0.007 1.510 (1.152–1.980) 0.002 0.103
Cardiac death 440 (5.2) 107 (3.7) 0.001 1.449 (1.173–1.790) 0.001 1.840 (1.329–2.483) <0.001 0.456
Re-MI 134 (1.7) 46 (1.7) 0.844 1.034 (0.740–1.446) 0.884 1.343 (0.905–1.912) 0.124 0.854
Any revascularization 240 (3.2) 94 (3.5) 0.428 1.101 (0.868–1.398) 0.428 1.015 (0.834–1.315) 0.914 0.428
ST (definite or probable) 65 (0.8) 24 (0.8) 0.813 1.058 (0.663–1.690) 0.813 1.114 (0.676–1.836) 0.672 0.813
HR, hazard ratio; CI, confidence interval; MACEs, major adverse cardiac events; Re-MI, recurrent myocardial infarction; ST, stent
thrombosis, Pre-PCI, pre-percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction; 1G-DES, first-generation
drug-eluting stent, 2G-DES, second-generation DES; LVEF, left ventricular ejection fraction; SBP, systolic blood pressure, DBP, diastolic
blood pressure; CPR, cardiopulmonary resuscitation; DM, diabetes mellitus; PCI, percutaneous coronary intervention; CVA, cerebrovascular
accidents; CK-MB, creatine kinase myocardial band; NT-ProBNP, N-terminal pro-brain natriuretic peptide; hs-CRP, high-sensitivity-C-
reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ACEIs, angiotensin converting enzyme inhibitors; ARBs,
angiotensin receptor blockers; CCB, calcium channel blocker, LM, left main coronary artery; LCx, left circumflex artery; RCA, right
coronary artery; IRA, infarct-related artery; ACC/AHA, American College of Cardiology/American Heart Association; GP, glycoprotein.
IVUS, intravascular ultrasound; OCT, optical coherence tomography; FFR, fractional flow reserve; SES, sirolimus-eluting stent; PES,
paclitaxel-eluting stent; ZES, zotarolimus-eluting stent; EES, everolimus-eluting stent. a Adjusted by male, Killip class I/II, SBP, CRP on
admission, dyslipidemia, previous PCI, peak CK-MB, peak troponin-I, NT-ProBNP, hs-CRP, serum creatinine, triglyceride, HDL-cholesterol,
clopidogrel, ticagrelor, prasugrel, cilostazole, beta-blocker, CCB, LCx (IRA), single-vessel disease, two-vessel disease, ≥three-vessel disease,
ACC/AHA type B1/B2/C lesions, in-hospital GP IIb/IIIa inhibitor, IVUS, OCT, FFR, culprit-only PCI, stent diameter, and number of stents
(Table 1). b Adjusted by Killip class I/II, CRP on admission, dyslipidemia, previous PCI, serum creatinine, total cholesterol, triglyceride,
HDL-cholesterol, LDL-cholesterol, clopidogrel, ticagrelor, prasugrel, cilostazole, beta-blocker, CCB, LAD and RCA (IRA and treated
vessel), single-vessel disease, ≥three-vessel disease, ACC/AHA type B1/B2/C lesions, in-hospital GP IIb/IIIa inhibitor, IVUS, OCT, FFR,
culprit-only PCI, stent diameter, and number of stents (Table 1). c Adjusted by LVEF, BMI, Killip class I/IV, SBP, DBP, cardiogenic shock,
CRP on admission, peak CK-MB, peak troponin-I, blood glucose, beta-blocker, ACEI/ARB, CCB, LM, LAD, LCx, and RCA (IRA), LM,
LAD, and RCA (treated vessel), ACC/AHA type B1/B2/C lesions, in-hospital GP IIb/IIIa inhibitor, stent length, and number of stents
(Supplementary Table S5). d Adjusted by age, LVEF, BMI, Killip class I/II/IV, SBP, cardiogenic shock, DM, previous CVA, peak CK-MB,
peak troponin-I, blood glucose, NT-ProBNP, hs-CRP, total cholesterol, LDL-cholesterol, ACEI/ARB, CCB, LM, LAD, and RCA (IRA), LM,
LAD, LCx, and RCA (treated vessel), single-vessel disease, ≥three-vessel disease, ACC/AHA type B1/B2/C lesions, in-hospital GP IIb/IIIa
inhibitor, IVUS, other stents, culprit-only PCI, stent length, and number of stents (Supplementary Table S5).
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Table 3. Clinical outcomes by Kaplan-Meier analysis and Cox-proportional hazard ratio analysis at 2 years.
Total Population (Pre-PCI TIMI 0/1 vs. Pre-PCI TIMI 2/3)
Cumulative Events (%) Unadjusted Adjusted a
Outcomes
Pre-PCI TIMI 0/1
Group A1 + B1
(n = 12,862)
Pre-PCI TIMI 2/3
Group A2 + B2
(n = 5029)
Log-Rank HR (95% CI) p-Value HR (95% CI) p-Value
MACEs 1343 (10.7) 466 (9.5) 0.012 1.145(1.030–1.272) 0.012
1.210
(1.075–1.398) 0.005
All-cause death 749 (5.9) 224 (4.5) <0.001 1.322(1.139–1.535) <0.001
1.350
(1.095–1.699) 0.006
Cardiac death 666 (5.2) 183 (3.7) <0.001 1.437(1.220–1.692) <0.001
1.498
(1.180–1.910) 0.001















Total population (1G-DES vs. 2G-DES)
Cumulative Events (%) Unadjusted Adjusted b
Outcomes 1G-DES Group A1+ A2 (n = 6364)
2G-DES
Group B1 + B2
(n = 11,527)
Log-Rank HR (95% CI) p-Value HR (95% CI) p-Value
MACEs 726 (11.4) 1083 (9.8) 0.001 1.176(1.070–1.292) 0.001
1.233
(1.095–1.388) <0.001
All-cause death 333 (5.2) 640 (5.7) 0.252 1.080(0.946–1.233) 0.253
1.086
(0.936–1.298) 0.351
Cardiac death 302 (4.7) 547 (4.8) 0.875 1.011(0.879–1.164) 0.875
1.045
(0.885–1.260) 0.641















a Adjusted by age, LVEF, BMI, Killip class I/II/IV, SBP, DBP, cardiogenic shock, DM, peak CK-MB, peak troponin-I, blood glucose, NT-
ProBNP, hs-CRP, total cholesterol, triglyceride, clopidogrel, ticagrelor, cilostazole, beta-blocker, ACEI/ARB, CCB, LM, LAD, LCx, and RCA
(IRA and treated vessel), single-vessel disease, ≥three-vessel disease, ACC/AHA type B1/B2/C lesions, in-hospital GP IIb/IIIa inhibitor,
IVUS, SES, PES, ZES, EES, other stent, culprit-only PCI, complete revascularization, stent length, and number of stents (Supplementary
Table S6). b Adjusted by male, BMI, Killip class I/II, SBP, CPR on admission, dyslipidemia, previous MI, previous PCI peak CK-MB,
peak troponin-I, NT-ProBNP, hs-CRP, serum creatinine, triglyceride, HDL-cholesterol, LDL-cholesterol, clopidogrel, ticagrelor, prasugrel,
cilostazole, beta-blocker, CCB, LAD (IRA), RCA (IRA and treated vessel), single-vessel disease, two-vessel disease, ≥three-vessel disease,
ACC/AHA type B1/B2/C lesions, in-hospital GP IIb/IIIa inhibitor, IVUS, OCT, FFR, culprit-only PCI, stent diameter, and number of stents
(Supplementary Table S6).
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Figure 2. Kaplan–Meier analysis for the MACEs (A), all-cause death (B), cardiac death (C), Re-MI (D), any repeat revascular-
ization (E), and stent thrombosis (F) at 2 years. MACEs, major adverse cardiac events; Re-MI, recurrent myocardial infarction;
Pre-TIMI, pre-percutaneous coronary intervention thrombolysis in myocardial infarction flow grade; 1G, first-generation;
2G, second-generation; DES, drug-eluting stent.
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Figure 3. Kaplan–Meier analysis of any repeat revascularization according to the kinds of deployed stents. SES, serolimus-
eluting stent; PES, paclitaxel-eluting stent; ZES, zotarolimus-eluting stent; EES, everolimus-eluting stent; BES, biolimus-
eluting stent; Pre-PCI, pre-percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction.
In the pre-TIMI 0/1 group, after adjustment, the cumulative incidence of MACEs (aHR:
1.348; 95% CI: 1.84–1.536; p < 0.001) and any repeat revascularization (aHR: 1.938; 95% CI:
1.605–2.340; p < 0.001) were significantly higher in the 1G-DES groups than in the 2G-DES
groups. Similarly, in the pre-TIMI 2/3 group, after adjustment, the cumulative incidence of
MACEs (aHR: 1.415; 95% CI: 1.142–1.953; p = 0.002) and any repeat revascularization (aHR:
1.674; 95% CI: 1.244–2.352; p = 0.001) were also significantly higher in the 1G-DES groups
than in the 2G-DES groups. However, in the pre-TIMI 0/1 and 2/3 groups, the cumulative
incidence of all-cause death, CD, re-MI, and ST were similar between the 1G-DES and
2G-DES groups.
Figure 3 and Table 4 show the cumulative incidence of any repeat revascularization
according to deployed stent type. Moreover, Supplementary Tables S1–S3 show the baseline
characteristics according to deployed stent type. Paclitaxel-eluting stents (PES) showed a
higher cumulative incidence of any repeat revascularization than sirolimus-eluting stents
(SES) in the total study population (aHR: 1.415; 95% CI; 1.132–1.769; p = 0.002), pre-
TIMI 0/1 (aHR: 1.374; 95% CI; 1.049–1.798; p = 0.021), and pre-TIMI 2/3 (aHR: 1.533;
95% CI; 1.035–2.330; p = 0.034) groups. However, sirolimus-eluting stent showed similar
cumulative incidence of any repeat revascularization compared with zotarolimus-eluting
stent and biolimus-eluting stent in both pre-TIMI 0/1 and 2/3 groups. Supplementary
Table S4 shows the independent predictors for MACEs and any repeat revascularization
in the total study population at 2 years. Old age (≥65 years), cardiogenic shock, CPR
on admission, diabetes mellitus, BB, left main coronary artery as a treated vessel, single-
vessel disease, more than three diseased vessels, and culprit-only PCI were significant
independent predictors for both MACEs and any repeat revascularization. Supplementary
Table S5 shows baseline characteristics between pre-TIMI 0/1 and 2/3 in 1G-DES or
2G-DES groups. Supplementary Table S6 shows baseline characteristics between pre-
TIMI 0/1 and 2/3 groups or between 1G-DES and 2G-DES groups in the total study
population. Subgroup analyses for MACEs and any repeat revascularization are shown in
Supplementary Figure S1. In the pre-TIMI 0/1 group, 2G-DES may be preferred to 1G-DES
to reduce MACEs and any repeat revascularization in patients who did not experience
cardiogenic shock or who did not receive CPR on admission. In the pre-TIMI 2/3 group,
2G-DES may be beneficial to the patients who did not receive CPR on admission, who
received culprit-only PCI, or who received more than 3 mm sized DES in reducing MACEs
and any repeat revascularization compared with 1G-DES in this study.
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Log-Rank HR (95% CI) p-Value HR (95% CI) p-Value
SES vs. PES 102 (4.7) 132 (6.9) 0.004 1.464 (1.131–1.896) 0.004 1.374 (1.049–1.798) 0.021 d
SES vs. ZES 102 (4.7) 107 (3.5) 0.027 1.358 (1.035–1.781) 0.027 1.577 (1.184–2.100) 0.002 e
SES vs. EES 102 (4.7) 89 (2.7) <0.001 1.813 (1.364–2.409) <0.001 2.441 (1.773–3.358) <0.001 d
SES vs. BES 102 (4.7) 31 (3.4) 0.069 1.449 (0.969–2.166) 0.071 1.948 (1.220–3.109) 0.005 e
PES vs. ZES 132 (6.9) 107 (3.5) <0.001 2.006 (1.580–2.547) <0.001 2.025 (1.557–2.634) <0.001 d
PES vs. EES 132 (6.9) 89 (2.7) <0.001 2.637 (2.015–3.450) <0.001 2.919 (2.141–3.981) <0.001 d




Log-Rank HR (95% CI) p-Value HR (95% CI) p-Value
SES vs. PES 47 (4.3) 62 (7.1) 0.005 1.716 (1.175–2.507) 0.005 1.553 (1.035–2.330) 0.034 d
SES vs. ZES 47 (4.3) 36 (3.4) 0.342 1.234 (0.799–1.905) 0.343 1.189 (0.745–1.896) 0.468
SES vs. EES 47 (4.3) 29 (2.6) 0.020 1.721 (1.083–2.735) 0.022 1.853 (1.117–3.074) 0.017 d
SES vs. BES 47 (4.3) 13 (3.8) 0.653 1.151 (0.623–2.128) 0.653 1.057 (0.516–2.164) 0.879
PES vs. ZES 62 (7.1) 36 (3.4) <0.001 2.085 (1.433–3.033) <0.001 1.955 (1.278–2.991) 0.002 d
PES vs. EES 62 (7.1) 29 (2.6) <0.001 2.977 (1.915–4.628) <0.001 2.873 (1.754–4.709) <0.001 d




Log-Rank HR (95% CI) p-Value HR (95% CI) p-Value
SES vs. PES 149 (4.6) 194 (7.0) <0.001 1.541 (1.245–1.908) <0.001 1.415 (1.132–1.769) 0.002 d
SES vs. ZES 149 (4.6) 143 (3.5) 0.019 1.315 (1.045–1.654) 0.019 1.423 (1.116–1.813) 0.004 e
SES vs. EES 149 (4.6) 118 (2.6) <0.001 1.774 (1.393–2.258) <0.001 2.203 (1.684–2.883) <0.001 d
SES vs. BES 149 (4.6) 44 (3.5) 0.079 1.350 (0.964–1.890) 0.080 1.610 (1.093–2.373) 0.016 e
PES vs. ZES 194 (7.0) 143 (3.5) <0.001 2.033 (1.663–2.485) <0.001 1.977 (1.583–2.469) <0.001 d
PES vs. EES 194 (7.0) 118 (2.6) <0.001 2.728 (2.170–3.430) <0.001 2.823 (2.174–3.665) <0.001 d
PES vs. BES 194 (7.0) 44 (3.5) <0.001 2.070 (1.492–2.872) <0.001 2.014 (1.370–2.960) <0.001 d
HR, hazard ratio; CI, confidence interval; Pre-PCI, pre-percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction;
1G-DES, first-generation drug-eluting stent, 2G-DES, second-generation DES; SES, sirolimus-eluting stent; PES; paclitaxel-eluting stent;
ZES, zotarolimus-eluting stent; EES, everolimus-eluting stent; BES, biolimus-eluting stent; BMI, body mass index; LVEF, left ventricular
ejection fraction; SBP, systolic blood pressure, CPR, cardiopulmonary resuscitation; MI, myocardial infarction; PCI, percutaneous coronary
intervention; DM, diabetes mellitus; CK-MB, creatine kinase myocardial band; NT-ProBNP, N-terminal pro-brain natriuretic peptide;
hs-CRP, high sensitivity-C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; CCB, calcium channel blocker;
IRA, infarct-related artery; LAD, left anterior descending coronary artery; RCA, right coronary artery; LM, left main coronary artery;
ACC/AHA, American College of Cardiology/American Heart Association; GP, glycoprotein; IVUS, intravascular ultrasound; OCT, optical
coherence tomography; FFR, fractional flow reserve; PCI, percutaneous coronary intervention. a Adjusted by male, age, LVEF, BMI, Killip
class I/II/III, SBP, CPR on admission, dyslipidemia, previous MI, previous PCI, peak CK-MB, troponin-I, NT-ProBNP, high-sensitivity
CRP, serum creatinine, total cholesterol, triglyceride, HDL-cholesterol, aspirin, clopidogrel, ticagrelor, prasugrel, cilostazole, beta-blocker,
CCB, LAD, and RCA (IRA and treated vessel), LM (treated vessel), single-vessel disease, two-vessel disease, ≥three-vessel disease,
ACC/AHA type B2/C lesions, in-hospital GP IIb/IIIa, IVUS, OCT, FFR, culprit-only PCI, stent diameter, stent length, and number of stents
(Supplementary Table S1). b Adjusted by male, age, LVEF, Killip class I/II, cardiogenic shock, CPR on admission, DM, previous PCI, peak
CK-MB, NT-ProBNP, total cholesterol, HDL-cholesterol, LDL-cholesterol, clopidogrel, ticagrelor, prasugrel, cilostazole, beta-blocker, CCB,
LAD (IRA), RCA (IRA and treated vessel), single-vessel disease, ≥three-vessel disease, ACC/AHA type B1/B2/C lesions, in-hospital GP
IIb/IIIa, IVUS, OCT, FFR, culprit-only PCI, stent diameter, stent length, and number of stents (Supplementary Table S2). c Adjusted by
male, age, LVEF, BMI, Killip class I/II/III, cardiogenic shock, CPR on admission, dyslipidemia, previous PCI, peak CK-MB, troponin-I,
NT-ProBNP, hs-CRP, serum creatinine, total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol, clopidogrel, ticagrelor, prasugrel,
cilostazole, beta-blocker, CCB, LAD, and RCA (IRA and treated vessel), LM (treated vessel), single-vessel disease, two-vessel disease,
≥three-vessel disease, ACC/AHA type B1/B2/C lesions, in-hospital GP IIb/IIIa, IVUS, OCT, FFR, culprit-only PCI, stent diameter, stent
length, and number of stents (Supplementary Table S3). d Statistically significant association after adjustment for multiple comparisons. e
p-value was <0.05 but did not achieve statistical significance after adjustment for multiple comparisons.
4. Discussion
In this retrospective cohort study, we compared the two-year major clinical outcomes
of the 1G-DES and 2G-DES groups using pre-TIMI. The main findings were as follows.
First, in the total study population, the cumulative incidence of MACEs, all-cause death,
and CD were significantly higher in the pre-TIMI 0/1 group (Groups A1 and B1) than in the
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pre-TIMI 2/3 group (Groups A2 and B2). Second, the cumulative incidence of MACEs and
any repeat revascularization were significantly higher in the 1G-DES group than in the 2G-
DES group among the total study population and in both the individual groups (pre-TIMI
0/1 or 2/3). Third, however, sirolimus-eluting stent showed similar cumulative incidence
of any repeat revascularization compared with zotarolimus-eluting stent and biolimus-
eluting stent in both pre-TIMI 0/1 and 2/3 groups. Fourth, the cumulative incidence of
all-cause death, re-MI, and ST were similar between the 1G-DES and 2G-DES groups.
Stone et al. [18] and De Luca et al. [19] demonstrated that pre-PCI TIMI flow grade
3 is an independent predictor of mortality in AMI. Moreover, Brodie et al. [20] showed
that procedural success rates were higher in patients with a pre-TIMI 2/3 than in those
with a pre-TIMI 0/1 (97.4% vs. 93.8%, p = 0.02). The main advantages of early IRA patency
are related with easier guidewire passage and a smaller amount thrombus burden with
a relatively lower risk of distal embolization [5]. Others include decreased myocardial
infarct size, serious arrhythmic cardiac events, and in-hospital death [21]. In the total
study population, our results showing the better major clinical outcomes in the pre-TIMI
2/3 group regarding the cumulative incidences of MACEs, all-cause death, and CD were
consistent with previous findings [18,22].
During the two-year follow-up period, in both the individual groups (pre-TIMI 0/1 or
2/3), the cumulative incidence of any repeat revascularization was higher in the 1G-DES
groups than in the 2G-DES groups and the increased incidence of any repeat revascular-
ization was associated with an increased incidence of MACEs in the 1G-DES in our study
(Tables 2 and 3). Based on our results, 2G-DES showed sustained better clinical outcomes
than 1G-DES with respect to any repeat revascularization regardless of pre-PCI TIMI flow
grade. Therefore, although pre-TIMI is an independent predictor of survival in patients
with STEMI, it is not significantly related to the major clinical outcomes between 1G-DES
and 2G-DES after successful PCI. 2G-DES is using the newer metallic alloys (such as cobalt-
chromium and platinum-chromium), allowing thinner strut stent platforms and use of
new drug carriers offering reduced incidence of revascularization [1–3]. De Luca et al. [23]
reported that everolimus-eluting stent was associated with a lower TVR (14.2% vs. 20.1%;
HR: 0.63; 95% CI: 0.42–0.96; p = 0.03) than the 1G-DES. More recently, Kim et al. [15]
reported that the any repeat revascularization rate was significantly higher in the 1G-DES
group than in the 2G-DES group in both culprit-only PCI (aHR: 1.345; 95% CI: 1.145–1.705;
p = 0.001) and multivessel PCI (aHR: 2.444; 95% CI: 1.549–3.855; p < 0.001) in their 7266
STEMI patients. Single-center registry data [24] also showed that the five-year cumulative
incidence of any repeat revascularization was significantly higher in the 1G-DES group
than in the 2G-DES group (16.8% vs. 9.1%, p = 0.018) in their 1016 AMI patients. However,
in the three-year results of the XAMI (Xience V stent vs. Cypher Stent in Primary PCI
for Acute Myocardial Infarction) trial [2], major clinical outcomes were similar between
1G-DES and 2G-DES. Wu et al. [25] showed that the 2G-DES failed to demonstrate a superi-
ority over the 1G-DES in reducing the incidence of TLR (relative risk (RR): 1.73; 95% CI:
0.83–3.64; p = 0.15), MACEs (RR: 0.97; p = 0.90), or all-cause death (RR: 1.00; p = 1.0) in their
meta-analysis. It was unclear whether the clinical outcomes of the 2G-DES and the 1G-DES
are identical in AMI settings with higher possible hypercoagulable coronary lesions [2].
Otsuka et al. [26] reported that the frequency of neoatherosclerosis were similar between
1G-DES and 2G-DES. A possible explanation for these conflicting results may be related
to the different characteristics of the constituents (e.g., STEMI and non-STEMI) in the
total study population, differences in follow-up duration, and differences in comparison
methods (by individual stent or by group). To clarify our study results, we re-analyzed the
cumulative incidence of any repeat revascularization according to types of deployed stents
in the total study population, as shown in Table 4 and Figure 3. In this study, PES showed
a higher cumulative incidence of any repeat revascularization than SES in the total study
population, pre-TIMI 0/1 group, and pre-TIMI 2/3 group. A previous meta-analysis [27]
also showed that SES was superior to PES in terms of a significant reduction in the risk
of reintervention (HR: 0.74; 95% CI: 0.63–0.87; p < 0.001). However, sirolimus-eluting
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stent showed similar cumulative incidence of any repeat revascularization compared with
zotarolimus-eluting stent and biolimus-eluting stent in both pre-TIMI 0/1 and 2/3 groups.
In this study, the cumulative incidence of ST was similar between the 1G-DES and
2G-DES groups in the total or individual groups. Compared to the 1G-DES group, the
2G-DES group included a higher number of patients who received more recently developed
and more potent and rapid-acting thienopyridines such as ticagrelor or prasugrel (Table 1).
However, the number of these patients was relatively small (<9%) and the prescription rate
of clopidogrel (97.3% vs. 83.7%, p < 0.001; or 97.7% vs. 84.3%, p < 0.001) was significantly
higher in the 1G-DES group than in the 2G-DES group. Furthermore, the prescription rate of
cilostazole was also higher in the 1G-DES group than in the 2G-DES group (33.7% vs. 17.5%,
p < 0.001; or 36.1% vs. 17.0%, p < 0.001). Therefore, these relatively higher prescription
rates of clopidogrel and cilostazole in the 1G-DES group could have induced this similar
ST rate between the two groups.
Because a large number of high-volume PCI community and teaching hospitals partic-
ipated in this multicenter registry analysis, our study may provide impressive information
about the comparative benefit of 2G-DES for reducing any revascularization rate compared
with 1G-DES in patients with STEMI focused on pre-TIMI.
This study had several limitations. First, the two-year follow-up period in this study
was not long enough in order to estimate long-term major clinical outcomes. Moreover,
in this study, the temporal range of the inclusion period is large (10 years, 2005–2015)
and 1G-DES were probably used several years before 2G-DES (Supplementary Figure S2).
Despite the fact that there is a thorough multivariate adjustment, this situation can lead to
two types of uncontrolled biases: (1) Historical bias: General management of patient during
the early years might be significantly different that in the late years not only because of
invasive or medical treatment but also because or unknown or uncontrolled factors, and (2)
during the years where 1G DES and 2G DES coexisted, the operator election of one or other
type of device could be influenced by patient’s characteristics. This point is another weak
point of this study. Second, because this was a non-randomized retrospective study, there
were some underreported and/or missed data. Third, because this study was conducted
based on discharge medications and owing to the limitations of registry study, we did
not precisely know the adherence or non-adherence of enrolled patients to these drugs
during the follow-up period. Fifth, despite multivariate analysis, variables not included
in the KAMIR may have affected the study outcomes. Finally, although pre-TIMI is easy
and inexpensive, it could be a suboptimal, incomplete measure of myocardial perfusion.
Finally, considering that there is a considerable overall mortality, when analyzing single
outcomes or composite outcomes not containing all-cause death, a competing risk analysis
should be performed. However, in this study, 2.1% (14/676) of the cumulative incidence of
any repeat revascularization included all-cause death.
5. Conclusions
In conclusion, in this study, 2G-DES showed better clinical outcomes than 1G-DES
with respect to MACEs and any repeat revascularization regardless of pre-PCI TIMI flow
grade. However, more research is needed to support these results.
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